References
- Dighiero G., Travade P., Chevret S., Fenaux P., Chas-Tang C., Binet J.-L., and the French Cooperative Group on CLL. B-cell chronic lymphocytic leukemia: present status and future directions. Blood 1991; 78: 1901–1914
- Keating M.J. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin. Oncol. 1990; l7(Suppl. 8)49–62
- Beutler E. Drug profiles. Cladribine (2-chlorodeox-yadenosine). Lancet 1992; 340: 952–956
- Juliusson G., Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine (CdA) in previously treated patients with B-cell chronic lymphocytic leu kemia: response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 1993; 11: 679–689
- Keating M.J., O'Brien S., Kantarjian H., Plunckett W., Estey E., Freireich E. Long term follow-up of patients with chronic lymphocytic leukemia (CLL) treated with fludarabine (Flu) as a single agent. Blood 1992; 80(Suppl. l)159a, (abstract)
- Cheson B.D., Bennett J.M., Rai K.R., Grever M.R., Kay N.E., Schiffer C.A., Oken M.M., Keating M.J., Boldt D.H., Kempin S.J., Foon K.A. Guide lines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am. J. Haematol. 1988; 29: 152–163
- Juliusson G., Elmhom-Rosenborg A., Liliemark J. Response to 2-chloro-2′-deoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. 1992; 327: 1056–1061
- Kazimierczuk Z., Cottam H.B., Ravankar G.R., Robins R.K. Synthesis of 2′-deoxytubericin, 2′-deoxy-adenosine and related 2′-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. J. Am. Chem. Soc. 1984; 106: 6379–6382
- Juliusson G., Liliemark J. 2-Chlorodeoxyaden-osine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. 1993; 328: 812–813, (let ter)
- Petzer A.L., Bilgeri R., Zilian U., Haun M., Geisen F.H., Pragnell I., Braunsteiner H., Konwalinka G. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood 1991; 78: 2583–2587
- Dimopoulos M.A., Kantarjian H., Estey E., O'Brien S., Delasalle K., Keating M.J., Freireich E.J., Alexanian R. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann. Int. Med. 1993; 118: 195–198
- Liliemark J., Albertioni F., Hassan M., Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: Alternative routes of admin istration. J. Clin. Oncol. 1992; 10: 1514–1518
- Juliusson G., Liliemark J., Hippe E., Blichfeldt P., Wall-Man K., Hagberg H., Stolt C.-M., Bergheim J., Winquist I., Hedenus M., Carlsson M., Wen L., Hellquist L., Brinck L., Kristofferson R., Ly B.E., Väärt J. Subcutaneous injections of 2-chloro-2′-deoxyadenosine (CdA) as treatment for symptomatic hairy cell leukemia (HCL). Blood 1992; 80(Supp1. l)359a, (abstract)
- Juliusson G., Liliemark J. Complete remission from oral cladribine in chronic lymphocytic leukemia. Lancet 1993; 341: 54, (letter)
- Rabinowe S.N., Soiffer R.J., Gribben J.G., Freedman A.S., Pesek K.W., Daley H.L., Daley J.F., Spector N.L., Anderson K.C., Robertson M.J., Ritz J., Nad-Ler L.M. Autologous and allogeneic bone marrow transplantation (BMT) for patients with Binet stage B and C B-cell chronic lymphocytic leukemia (B-CLL). Blood 1992; 80(Suppl. l): 170a, (abstract)